Lorus Files IND for Anti-Cancer Drug Candidate

2 June 2010 (Last Updated June 2nd, 2010 18:30)

Lorus Therapeutics has filed an investigational new drug (IND) application with the US Food and Drug Administration for LOR-253, an anti-cancer drug candidate. The application is for a first-in-human phase I dose escalation trial in advanced or metastatic solid tumours to assess antitum

Lorus Therapeutics has filed an investigational new drug (IND) application with the US Food and Drug Administration for LOR-253, an anti-cancer drug candidate.

The application is for a first-in-human phase I dose escalation trial in advanced or metastatic solid tumours to assess antitumour activity, safety and tolerability in cancer patients.

The trial will be conducted at Memorial Sloan-Kettering Cancer Center in New York, US.

Preclinical studies have demonstrated that the compound has selective and antitumour activity against colon and non-small cell lung cancer, and is less toxic.